셀룰라이트 치료 시장 : 시술 유형별, 셀룰라이트 유형별, 최종 사용자별 - 세계 기회 분석 및 산업 예측(2021-2031년)

The global cellulite treatment market was valued at $2,140.0 million in 2021, and is projected to reach $5,729.06 million by 2031, registering a CAGR of 10.3% from 2022 to 2031.

Cellulite is the herniation of subcutaneous fat within fibrous connective tissue that manifests as skin dimpling and nodularity, often on the pelvic region (specifically the buttocks), lower limbs, and abdomen. The condition is most prevalent in women.

The increase in obesity rate owing to fast food consumption and sedentary lifestyle drive the growth of the market. Weight gain and high obesity are responsible for the development of cellulites. In addition, the increase in the number of cosmetic procedures and the rise in a number of cosmetic clinics contribute toward the growth of the market. For instance, according to International Society of Aesthetic Plastic Surgery (ISAPS) survey, in 2020 about 10,129,528 cosmetic surgical procedures are carried worldwide. The rise in demand for attractive physical appearance in men and women owing to social media influence and celebrities who are popular among the young generation, motivate them to look aesthetically appealing, which provides ample opportunities for market growth. The cellulite treatment, reduces the fat depositions especially from around the thighs and buttocks which further enhances the appearance.

The increase in demand for minimally invasive cosmetic procedures, rise in popularity of cosmetic procedures and genetical factors predominantly in women contribute toward the market growth. Increase in awareness about advanced non-invasive cellulite treatment, and surge in number of cosmetology surgeons are expected to drive the market growth in the coming years.

Moreover, the increase in R&D activities for development of advanced cellulite treatment, product approvals and novel product launch in the market by key players boost the market growth. For instance, in July 2020, Endo International plc, a highly-focused specialty branded and generics pharmaceutical company, has received U.S. Food and Drug Administration (FDA) approval for its, Qwo (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. However, the high cost of advanced cellulite treatment and underdeveloped health care infrastructure in developing countries may hinder the growth of the market.

The cellulite treatment market is segmented on the basis of procedure type, cellulite type, end user and region. By procedure type, the market is divided into non-invasive, minimal invasive and topical. By cellulite type, the market is classified into soft cellulite, hard cellulite, and edematous cellulite. The soft cellulite segment is further divided into male and female. The hard cellulite segment is further bifurcated into male and female. By end user, the market is categorized into hospitals, clinics & beauty centers, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include ABBVIE, Bausch Health Companies Inc, Candela Syneron, Cynosure, Galderma SA, Johnson & Johnson, Merz Pharma GmbH & Co. KGaA, Sientra Inc, Sinclair Pharma and Teoxane Laboratories.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cellulite treatment market analysis from 2021 to 2031 to identify the prevailing cellulite treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the cellulite treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global cellulite treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Procedure Type

• Non-invasive
• Minimally Invasive
• Topical

By Cellulite Type

• Soft Cellulite
  • Gender
  • Male
  • Female
• Hard Cellulite
  • Gender
  • Male
  • Female
• Edematous

By End User

• Hospitals
• Clinics and Beauty Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • Abbvie Inc
  • Candela Syneron
  • Cynosure Technologies
  • Merz Pharma GmbH & Co. KGaA
  • Bausch Health Companies Inc.
  • Hologic Inc
  • Zimmer Aesthetics
  • Galderma SA
  • Sinclair Pharmaceuticals Limited
  • Endo International plc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Non-invasive
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Minimally Invasive
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country
• 4.4 Topical
  • 4.4.1 Key market trends, growth factors and opportunities
  • 4.4.2 Market size and forecast, by region
  • 4.4.3 Market analysis by country

CHAPTER 5: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Soft Cellulite
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
  • 5.2.4 Soft Cellulite Cellulite Treatment Market by Gender
    • 5.2.4.1 Male Market size and forecast, by region
    • 5.2.4.2 Female Market size and forecast, by region
• 5.3 Hard Cellulite
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
  • 5.3.4 Hard Cellulite Cellulite Treatment Market by Gender
    • 5.3.4.1 Male Market size and forecast, by region
    • 5.3.4.2 Female Market size and forecast, by region
• 5.4 Edematous
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country

CHAPTER 6: CELLULITE TREATMENT MARKET, BY END USER

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospitals
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Clinics and Beauty Centers
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
• 6.4 Others
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country

CHAPTER 7: CELLULITE TREATMENT MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Procedure Type
  • 7.2.3 North America Market size and forecast, by Cellulite Type
    • 7.2.3.1 North America Soft Cellulite Cellulite Treatment Market by Gender
    • 7.2.3.2 North America Hard Cellulite Cellulite Treatment Market by Gender
  • 7.2.4 North America Market size and forecast, by End User
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Procedure Type
    • 7.2.5.1.2 Market size and forecast, by Cellulite Type
    • 7.2.5.1.3 Market size and forecast, by End User
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Procedure Type
    • 7.2.5.2.2 Market size and forecast, by Cellulite Type
    • 7.2.5.2.3 Market size and forecast, by End User
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Procedure Type
    • 7.2.5.3.2 Market size and forecast, by Cellulite Type
    • 7.2.5.3.3 Market size and forecast, by End User
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Procedure Type
  • 7.3.3 Europe Market size and forecast, by Cellulite Type
    • 7.3.3.1 Europe Soft Cellulite Cellulite Treatment Market by Gender
    • 7.3.3.2 Europe Hard Cellulite Cellulite Treatment Market by Gender
  • 7.3.4 Europe Market size and forecast, by End User
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Procedure Type
    • 7.3.5.1.2 Market size and forecast, by Cellulite Type
    • 7.3.5.1.3 Market size and forecast, by End User
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Procedure Type
    • 7.3.5.2.2 Market size and forecast, by Cellulite Type
    • 7.3.5.2.3 Market size and forecast, by End User
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Procedure Type
    • 7.3.5.3.2 Market size and forecast, by Cellulite Type
    • 7.3.5.3.3 Market size and forecast, by End User
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Procedure Type
    • 7.3.5.4.2 Market size and forecast, by Cellulite Type
    • 7.3.5.4.3 Market size and forecast, by End User
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Procedure Type
    • 7.3.5.5.2 Market size and forecast, by Cellulite Type
    • 7.3.5.5.3 Market size and forecast, by End User
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Procedure Type
    • 7.3.5.6.2 Market size and forecast, by Cellulite Type
    • 7.3.5.6.3 Market size and forecast, by End User
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Procedure Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Cellulite Type
    • 7.4.3.1 Asia-Pacific Soft Cellulite Cellulite Treatment Market by Gender
    • 7.4.3.2 Asia-Pacific Hard Cellulite Cellulite Treatment Market by Gender
  • 7.4.4 Asia-Pacific Market size and forecast, by End User
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Procedure Type
    • 7.4.5.1.2 Market size and forecast, by Cellulite Type
    • 7.4.5.1.3 Market size and forecast, by End User
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Procedure Type
    • 7.4.5.2.2 Market size and forecast, by Cellulite Type
    • 7.4.5.2.3 Market size and forecast, by End User
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Market size and forecast, by Procedure Type
    • 7.4.5.3.2 Market size and forecast, by Cellulite Type
    • 7.4.5.3.3 Market size and forecast, by End User
    • 7.4.5.4 India
    • 7.4.5.4.1 Market size and forecast, by Procedure Type
    • 7.4.5.4.2 Market size and forecast, by Cellulite Type
    • 7.4.5.4.3 Market size and forecast, by End User
    • 7.4.5.5 Rest of Asia-Pacific
    • 7.4.5.5.1 Market size and forecast, by Procedure Type
    • 7.4.5.5.2 Market size and forecast, by Cellulite Type
    • 7.4.5.5.3 Market size and forecast, by End User
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Procedure Type
  • 7.5.3 LAMEA Market size and forecast, by Cellulite Type
    • 7.5.3.1 LAMEA Soft Cellulite Cellulite Treatment Market by Gender
    • 7.5.3.2 LAMEA Hard Cellulite Cellulite Treatment Market by Gender
  • 7.5.4 LAMEA Market size and forecast, by End User
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Procedure Type
    • 7.5.5.1.2 Market size and forecast, by Cellulite Type
    • 7.5.5.1.3 Market size and forecast, by End User
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Procedure Type
    • 7.5.5.2.2 Market size and forecast, by Cellulite Type
    • 7.5.5.2.3 Market size and forecast, by End User
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Procedure Type
    • 7.5.5.3.2 Market size and forecast, by Cellulite Type
    • 7.5.5.3.3 Market size and forecast, by End User
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Procedure Type
    • 7.5.5.4.2 Market size and forecast, by Cellulite Type
    • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Abbvie Inc
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Candela Syneron
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Cynosure Technologies
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Merz Pharma GmbH & Co. KGaA
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Bausch Health Companies Inc.
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 Hologic Inc
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Zimmer Aesthetics
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Galderma SA
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Sinclair Pharmaceuticals Limited
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Endo International plc
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments